Lonvoguran
Asset
Disrupts KLKB1 in liver cells to reduce plasma kallikrein production.
- Stage
- Stage not known
- Modality
- Gene editing
- Target
- Not known
- 0
- Indications
- 0
- Trials
- 1
- Developer
Named in the news on Oct 29, 2026. news.google.com
Indications
0In the full profile
- Owner and partners1
- Signals3
Every asset’s record: target, stage, trials and the evidence behind it.